Table 5 Association between the -1327C>T hTERT genotype and the risk of clinical prostate cancer
From: hTERT promoter polymorphism, -1327C>T, is associated with the risk of epithelial cancer
Genotype | Genotype frequency distribution, n (%) | Crude OR | p-value | OR adjusted for age | p-value | |
|---|---|---|---|---|---|---|
Clinical prostate cancer patients | Control | (95% CI) | (95% CI) | |||
CC | 186 (48.1) | 137 (43.1) | 1 (reference) | 1 (reference) | ||
CT | 157 (40.6) | 142 (44.6) | 0.81 | 0.20 | 0.77 | 0.14 |
(0.59 - 1.12) | (0.54 - 1.09) | |||||
TT | 44 (11.4) | 39 (12.3) | 0.83 | 0.45 | 0.83 | 0.52 |
(0.51 - 1.35) | (0.48 - 1.44) | |||||
Dominant model | ||||||
CC | 186 (48.1) | 137 (43.1) | 1 (reference) | 1 (reference) | ||
CT + TT | 201 (51.9) | 181 (56.9) | 0.83 | 0.21 | 0.79 | 0.16 |
(0.61 - 1.13) | (0.56 - 1.10) | |||||
Recessive model | ||||||
CC + CT | 343 (88.6) | 279 (87.7) | 1 (reference) | 1 (reference) | ||
TT | 44 (11.4) | 39 (12.3) | 0.92 | 0.71 | 0.95 | 0.85 |
(0.58 - 1.46) | (0.57 - 1.60) | |||||
Additive model a | 0.88 | 0.25 | 0.86 | 0.25 | ||
(0.71 - 1.10) | (0.68 - 1.11) | |||||